DroneBase Secures $55 Million and Launches Next Stage of Advanced Inspection Under New Brand Zeitview
7.2.2023 14:00:00 EET | Business Wire | Press release
Further cementing its market leadership in advanced inspection software for energy and infrastructure, DroneBase has secured $55 million in investment and rebranded as Zeitview. Led by Valor Equity Partners, an operational growth investment firm backing technology and technology-enabled companies, the round was followed by existing investors Union Square Ventures, Upfront Ventures, Euclidean Capital, Energy Transition Ventures, and Hearst Ventures. The new funding will support the company’s AI-enabled software and global footprint in advanced inspection solutions. This announcement caps a year of rapid growth within the renewable sector, including the launch of the North American Solar Scan (NASS), the first standardized set of solar asset ratings to ensure better oversight of U.S. solar power plants. Last year, Zeitview inspected 43 GW of solar capacity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005174/en/
Zeitview inspection professionals use crewed aircraft and smartphone technologies to create relevant, flexible solutions for clients. Its accompanying software platform with deep insights and analytics allows clients to easily view data results anywhere. (Graphic: Business Wire)
As Zeitview, the company will continue building advanced inspection software that delivers fast, accurate insights, lowers costs for asset owners and improves performance and longevity. The name change comes with the company’s increasingly diverse data capture tools: alongside rotary wing drones, Zeitview inspection professionals use crewed aircraft and smartphone technologies to create relevant, flexible solutions for clients. Its accompanying software platform with deep insights and analytics allows clients to easily view data results anywhere.
“We appreciate how important time is to our customers: on the one hand, they need immediate and accurate analysis about the health of their assets; on the other, they are building energy and infrastructure resources to last for decades,” said Dan Burton, founder and chief executive officer at Zeitview. “We are confident that our AI-enabled software solutions can deliver that immediate answer and a long-term home for our customers, while we are increasingly agnostic about what tool we use to capture the most accurate data. We are grateful that Valor recognizes the power of our comprehensive services to support customers to build, protect, and maintain infrastructure across multiple asset classes and around the world. They understand transformational energy and infrastructure software and embrace businesses that use technology to solve operationally complex problems.”
Valor’s partnership enables Zeitview to continue transforming the aerial inspection industry with emerging technologies and exclusive AI software. Valor’s hands-on operational track record with complex software-led companies bolsters Zeitview’s commitment to increasing data capture capabilities through automation.
“Valor has been a long-term champion of data science and analytics to improve businesses,” said Vivek Pattipati, Partner at Valor Equity Partners. “With Zeitview’s continued expansion of services and commitment to delivering accurate, real-time insights through advanced inspection software, we are naturally mission-aligned. We look forward to supporting Zeitview as they launch this rebrand and enter the next phase of aerial imagery and data solutions.”
Zeitview means “time view” and better captures the nature of the company’s services and mission to accelerate the transition to renewable energy and sustainable infrastructure. In addition to providing real-time data, Zeitview offers long-term solutions to track changes across a period of time for an asset. Zeitview remains committed to building on the foundation of market leadership in drone services while engaging new tools for the evolving needs of the customer base. With last year’s launch of the NASS, the ability to serve as a one-stop shop for asset owners across multiple markets, and a continually expanding network of pilots around the globe, Zeitview is trailblazing the future of information gathering without limits.
For more information on how Zeitview makes aerial inspection data accessible across markets, please visit www.zeitview.com.
About Zeitview
For global customers in energy and infrastructure, Zeitview builds advanced inspection software that delivers fast, accurate insights, lowers costs, and improves asset performance and longevity. We are second to none at partnering with our customers to achieve flexible, long-term solutions across their multiple asset classes. Trusted by the largest enterprises in the world, Zeitview is active in over 70 countries. Learn more at www.zeitview.com.
About Valor Equity Partners
Valor Equity Partners is an operational growth investment firm focused on investing in high-growth companies across various stages of development. For decades, Valor has served its companies with unique expertise to solve the challenges of growth and scale. Valor partners with leading companies and entrepreneurs who are committed to the highest standards of excellence and the courage to transform their industries. For more information on Valor Equity Partners, please visit www.valorep.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005174/en/
Contact information
Technica Communications
Cait Caviness
zeitview@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom